Patents Assigned to Insulet Corporation
  • Patent number: 11957874
    Abstract: Some embodiments an infusion pump system can be configured to modify alarm limit parameters as the user's insulin load increases or decreases. Moreover, in particular embodiments, the infusion pump system can be configured to provide a “missed bolus” or “missed meal” alarm in response to the user's blood glucose characteristics, the user's insulin load information, or the like.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 16, 2024
    Assignee: INSULET CORPORATION
    Inventor: Mark C. Estes
  • Patent number: 11957875
    Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 16, 2024
    Assignee: INSULET CORPORATION
    Inventors: Yibin Zheng, Joon Bok Lee, Steven Cardinali, Jason O'Connor, Eric Benjamin, Ian McLaughlin, David Nazzaro, Ashutosh Zade
  • Patent number: 11935637
    Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 19, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Yibin Zheng, Jason O'Connor, Trang Ly, Eric Benjamin
  • Patent number: 11929158
    Abstract: A diabetes management system including a pump for dispensing a medicant and a control device for controlling the pump includes a user interface for controlling functions of the pump and providing information related to operation of the pump and other information. The user interface can display blood glucose information and insulin dosing data such that a user can appropriately act on the information and/or gain confidence that the diabetes management system is operating appropriately to manage the disease. User interfaces provided herein can include displays of current and projected glucose values, bolus calculators, charts displaying glucose levels and/or insulin delivery data, system maintenance reminders, system status information, patient configuration input screens, and log-in screens. Diabetes management systems can include insulin pumps, continuous glucose monitors, blood glucose monitors, mobile computing devices, servers, and/or other insulin delivery devices (e.g., insulin pens).
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: March 12, 2024
    Assignee: Insulet Corporation
    Inventors: Bryan Mazlish, Jeffrey Brewer, Lane Desborough, Jennifer Block, Robert Weishar, Alan Schachtely
  • Patent number: 11918783
    Abstract: Some embodiments an infusion pump system can be configured to modify alarm limit parameters as the user's insulin load increases or decreases. Moreover, in particular embodiments, the infusion pump system can be configured to provide a “missed bolus” or “missed meal” alarm in response to the user's blood glucose characteristics, the user's insulin load information, or the like.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: March 5, 2024
    Assignee: INSULET CORPORATION
    Inventor: Mark C. Estes
  • Patent number: 11911596
    Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: February 27, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Mengdi Li, Jason O'Connor, Yibin Zheng
  • Patent number: 11904140
    Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: February 20, 2024
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Yibin Zheng, Jason O'Connor, Trang Ly
  • Patent number: 11883632
    Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: January 30, 2024
    Assignee: INSULET CORPORATION
    Inventors: Jason O'Connor, Joon Bok Lee, Trang Ly, Yibin Zheng, Thomas Arnold Peyser, Jennifer Lena Schneider
  • Patent number: 11865299
    Abstract: Some embodiments of an infusion pump system can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin previously delivered to the user's body which has not yet acted. In particular embodiments, the TIL can account for both the bolus deliveries and the basal deliveries that have occurred over a period of time. Such information may be useful, for example, when the infusion pump is operated in conjunction with a continuous glucose monitoring device.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 9, 2024
    Assignee: Insulet Corporation
    Inventor: Mark C. Estes
  • Patent number: 11857763
    Abstract: A method may include displaying to a user an interface at which the user inputs a fear of hypoglycemia index (FHI), the FHI corresponding to an acceptable probability of a blood glucose level being below a threshold blood glucose level. The method may also include receiving blood glucose data for a person with diabetes (PWD). The method may additionally include calculating a probability of the PWD having a blood glucose level below the threshold blood glucose level based on the variability of the received blood glucose data. The method may also include setting one or more target blood glucose levels to align the probability of the PWD having a blood glucose level below the threshold blood glucose level with the acceptable probability associated with the user input FHI. The method may additionally include delivering insulin, using the insulin delivery device, based on the target blood glucose level.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: January 2, 2024
    Assignee: Insulet Corporation
    Inventors: Lane Desborough, Bryan Mazlish
  • Patent number: 11862318
    Abstract: In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: January 2, 2024
    Assignee: INSULET CORPORATION
    Inventors: George Crothall, Yean W. Chan
  • Patent number: 11833329
    Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: December 5, 2023
    Assignee: INSULET CORPORATION
    Inventors: Joon Bok Lee, Jason O'Connor, Yibin Zheng
  • Patent number: 11819675
    Abstract: A needle mechanism module for automatically inserting a fluid path into a patient for drug delivery is provided. The needle mechanism module can be a component of a wearable drug delivery device. The needle mechanism module can insert a needle and cannula into the patient responsive to activation of the drug delivery device by a user. After insertion, the needle can be automatically retracted, leaving only the cannula in the patient. As a result, discomfort of the user is reduced.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: November 21, 2023
    Assignee: INSULET CORPORATION
    Inventors: Maureen McCaffrey, Ian McLaughlin
  • Patent number: 11801344
    Abstract: Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: October 31, 2023
    Assignee: INSULET CORPORATION
    Inventors: Steven Cardinali, Joon Bok Lee, Jason O'Connor, Yibin Zheng
  • Patent number: 11798671
    Abstract: In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: October 24, 2023
    Assignee: INSULET CORPORATION
    Inventors: George Crothall, Yean W. Chan
  • Patent number: 11786668
    Abstract: A wearable drug delivery device that can deliver a liquid drug stored in a container to a patient is provided. The container can be a prefilled cartridge that can be loaded into the drug delivery device by the patient or that can be preloaded within the drug delivery device when provided to the patient. A sealed end of the container is pierced to couple the stored liquid drug to a needle conduit that is coupled to a needle insertion component that provides access to the patient. A drive system of the drug delivery device can expel the liquid drug from the cartridge to the patient through the needle conduit. The drive system can include a spring coupled to a plurality of force transfer elements. The force transfer elements can have a variety of shapes and configurations.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: October 17, 2023
    Assignee: INSULET CORPORATION
    Inventors: David Nazzaro, Ian McLaughlin, Jeff Barnes, Daniel Allis
  • Patent number: 11744944
    Abstract: Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: September 5, 2023
    Assignee: INSULET CORPORATION
    Inventors: Jason O'Connor, Daniel Allis, David Nazzaro, John R. Bussiere, John D'Arco
  • Patent number: 11746765
    Abstract: A low-force, non-displacement, micro/miniature valve and/or pump assembly is provided. A tube component having a first side port coupled to an inlet portion and a second side port coupled to an outlet portion can be selectively moved to alternatively couple the side ports to a first or second piston pump chamber. First and second pistons can be actuated after positioning the tube component to either draw in fluid or push out fluid from either the first or second piston pump chambers during each actuation of the pistons. The fluid can be drawn in from a reservoir and can be expelled to a patient for providing a dose of the fluid to the patient.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: September 5, 2023
    Assignee: INSULET CORPORATION
    Inventors: Daniel Allis, Ian McLaughlin, Kenneth Phillips
  • Patent number: D1007518
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: December 12, 2023
    Assignee: INSULET CORPORATION
    Inventors: Sandhya Pillalamarri, Jorge Borges, Susan Mercer
  • Patent number: D1010662
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: January 9, 2024
    Assignee: INSULET CORPORATION
    Inventors: Sandhya Pillalamarri, Jorge Borges, Susan Mercer